Ernst & Young has released Beyond Borders 2006, its annual review of the biotechnology sector globally, as well as of major regional markets, including the Americas, Asia-Pacific, and Europe. This Forbes article highlights the main points of the review, which marked 2006 as a robust year or growth.

• Alliances involving US companies reached 23 bln usd, an all time high.
• Capital raised by the worlds biotechnology companies surged 42 pct to 27.9 bln usd.
• Venture capital reached 5.4 bln usd, an all-time high.
• Global public company revenues grew by double-digit rates and crossed the 70 bln usd threshold for the first time.
• Double-digit revenue growth was achieved in Canada, the US and in Europe.
• The European biotech sector sustained its recovery of 2005, with 2006 marking a four-year Turnaround.

'The industry in the US has never been stronger and were seeing its success story spreading to other parts of the worldparticularly Europe, said Glen Giovannetti, Ernst & Youngs Global Biotechnology Leader.

You can download the E&Y reports here: Biotech Industry Overview and 2005 Year in Review (pdf, 210kb) Americas Biotech: Strength and Stability (pdf, 198kb) European Biotech: Back on Track (pdf, 200kb) Asia-Pacific Biotech: Emerging Focus (pdf, 163kb)